Abstract
The variability in disease outcome for indolent non-Hodgkin lymphomas (iNHL) and mantle-cell lymphoma (MCL) could be related to single nucleotide polymorphisms (SNPs) in genes that affect immune and inflammatory response. We investigated SNPs that could have a prognostic role for patients receiving bendamustine and rituximab (BR). All samples were genotyped for the IL-2 (rs2069762), IL-10 (rs1800890, rs10494879), VEGFA (rs3025039), IL-8 (rs4073), CFH (rs1065489) and MTHFR (rs1801131) SNPs by allelic discrimination assays using TaqMan SNP Genotyping Assays. We report a long-term follow-up analysis of 79 iNHL and MCL patients that received BR. Overall response rate was 97.5% (CR rate 70.9%). After a median follow-up of 63 months, median PFS and OS were not reached. We report a significant association between SNP in IL-2 (rs2069762) and reduced PFS and OS (p<.0001). We suggest a role for cytokine SNPs in disease outcome, while SNPs seem not related to long-term toxicity or secondary malignancies.
Authors’ contributions
Made substantial contributions to conception and design of the study and performed data analysis and interpretation: Cencini E, Sicuranza A
Performed data acquisition, as well as provided administrative, technical, and material support: Fabbri A, Marzano C, Pacelli P, Caroni F, Raspadori D
Supervised the manuscript: Bocchia M
Ethical approval
The study was conducted in accordance with Institutional Review Board requirements at study site and the Declaration of Helsinki and its amendments.
Disclosure statement
No potential conflict of interest was reported by the author(s).